AegirBio Past Earnings Performance
Past criteria checks 0/6
AegirBio's earnings have been declining at an average annual rate of -37.8%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 72.5% per year.
Key information
-37.8%
Earnings growth rate
-10.2%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -72.5% |
Return on equity | n/a |
Net Margin | -137,155.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AegirBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -49 | 11 | 45 |
31 Dec 23 | 0 | -60 | 18 | 42 |
30 Sep 23 | 0 | -367 | 20 | 46 |
30 Jun 23 | 0 | -362 | 25 | 40 |
31 Mar 23 | 0 | -364 | 28 | 41 |
31 Dec 22 | 2 | -363 | 28 | 39 |
30 Sep 22 | 3 | -88 | 40 | 49 |
30 Jun 22 | 8 | -100 | 42 | 53 |
31 Mar 22 | 15 | -94 | 38 | 52 |
31 Dec 21 | 13 | -92 | 36 | 51 |
30 Sep 21 | 12 | -103 | 29 | 75 |
30 Jun 21 | 7 | -81 | 23 | 61 |
31 Mar 21 | 0 | -73 | 22 | 52 |
31 Dec 20 | 0 | -62 | 19 | 45 |
Quality Earnings: 52Q is currently unprofitable.
Growing Profit Margin: 52Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 52Q is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare 52Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 52Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 52Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.